BANGKOK, Feb. 12, 2026 /PRNewswire/ — For today’s travellers, visiting Bangkok is about more than sightseeing. Many seek places that are easy to navigate, and reflective of the city’s modern lifestyle. Central Chidlom, known as The Store of Bangkok, brings shopping, dining, and world-class services into one destination. Guided by its core pillars: The Store of Curation, The Store of Design, The Store of Excellent Services, and The Store of Communities, Central Chidlom delivers thoughtful selection, design, and attentive service, welcoming everyone as part of #CitizenofChidlom.

Conveniently located with direct access to Chit-Lom BTS station, Central Chidlom is a must‑visit for international tourists. The store features an intuitive layout showcasing leading global brands alongside contemporary Thai designers, making discovery effortless across each floor. Guests can explore an extensive selection including Balenciaga, Bottega Veneta, Bvlgari (Pop–Up), Celine, Chanel, Christian Louboutin, Fendi, Gucci, Loewe, Louis Vuitton, Miu Miu, Prada, and more. Every zone is designed as a calm, elegant shop-in-shop atmosphere that reflects Bangkok’s modern character with global appeal.

Dining plays a key role in the experience. Central Chidlom offers a diverse range of international options across every floor, including signature destinations such as Lofter, Public Lane, and Public Market, with offerings ranging from Thai favourites to Chinese, Vietnamese, Italian, Indian cuisines, premium cafés, and Halal-friendly options. The inviting layout allows guests to enjoy a relaxed meal or take a convenient break during their shopping.

Central Chidlom enhances the visitor experience through services designed specifically for international travellers. The exclusive Personal Shopping service offers tailored guidance and personalised recommendations. Hotel delivery ensures a hands-free shopping experience, while interpreter services provide seamless communication in English, Chinese and Arabic. Prayer rooms offer comfort and inclusivity, and VAT refund with global payment options ensure effortless transactions. Together, these services make every visit flow with ease.

More than a department store, Central Chidlom represents The Store of Bangkok as a smart, stylish, and globally connected destination with a clear promise: everything you need, curated and effortlessly delivered.

Opening Hours: 10.00 am – 10.00 pm daily
How to Get There: Direct access from Chit-Lom BTS station; taxi and private car options available.
Website: www.central.co.th/en
Social media: https://www.facebook.com/CentralDepartmentStoreGlobal/

Source

SHANGHAI, Feb. 12, 2026 /PRNewswire/ — Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”) today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for AK3280, a novel anti-fibrotic therapy for the treatment of idiopathic pulmonary fibrosis (IPF). This clearance enables ArkBio to initiate a Phase 2 proof-of-concept (PoC) clinical trial of AK3280 in the United States.

The Phase 2 study is a multi-center, randomized, partially double-blind, placebo- and active-controlled trial designed to evaluate the efficacy, safety, and pharmacokinetics of oral AK3280 in patients with IPF. Authorization to proceed with a U.S. Phase 2 study represents a significant milestone in the global clinical development of AK3280.

IPF is a progressive, irreversible, and ultimately fatal interstitial lung disease characterized by fibrotic remodeling of lung tissue that leads to respiratory failure. The median survival following diagnosis is approximately 2–5 years. Currently approved therapies, including pirfenidone, nintedanib, and nerandomilast, can slow disease progression; however, their clinical benefit remains limited and they are frequently associated with gastrointestinal adverse events such as diarrhea and nausea. These tolerability challenges contribute to poor long-term adherence in a substantial proportion of patients. There remains a significant unmet need for therapies that provide improved efficacy with enhanced safety and tolerability profiles.

AK3280 is an optimized, small-molecule, broad-spectrum anti-fibrotic agent. In a Phase 2 proof-of-concept study conducted in China, AK3280 demonstrated encouraging clinical activity, including a statistically significant, dose-dependent absolute increase from baseline in forced vital capacity (FVC) at Week 24. Improvements were also observed across additional lung function parameters, suggesting meaningful clinical benefit. Importantly, AK3280 exhibited a favorable safety and tolerability profile, with no apparent increase in the gastrointestinal adverse effects commonly associated with currently available IPF therapies.

FDA clearance of the IND marks a pivotal step in the global development of AK3280. The upcoming international Phase 2 PoC trial is expected to generate critical clinical data to support future regulatory submissions and potential commercialization in the United States and other major markets. ArkBio remains committed to advancing AK3280 globally and to delivering more effective and better-tolerated treatment options for patients living with IPF.

About ArkBio

ArkBio is a commercial-stage biotechnology company focused on the discovery and development of innovative therapeutics for respiratory and pediatric diseases. Founded in 2014, the company has established proprietary technology platforms and a differentiated R&D pipeline through internal innovation and strategic collaborations.

Key pipeline assets include: Ziresovir (AK0529), the first direct-acting antiviral for RSV with positive pivotal Phase 3 results; AK3280, a potentially best-in-class anti-fibrotic agent with positive Phase 2 results in idiopathic pulmonary fibrosis; AK0901, approved in China for the treatment of ADHD and currently commercialized.

ArkBio has established strategic partnerships with multinational pharmaceutical companies and leading academic institutions, including Roche, Genentech, The Scripps Research Institute, and the Institute of Microbiology of the Chinese Academy of Sciences, as well as domestic and international biotech companies and venture capital partners.

For more information, please visit: www.arkbiosciences.com
Investor Inquiries: IR@arkbiosciences.com

Source

Including two new awardees, these remarkable results secure Sands China’s position as the leading integrated resort operator for world-class excellence 

MACAO, Feb. 12, 2026 /PRNewswire/ — Sands China Ltd. is celebrating record-breaking achievements that have redefined luxury hospitality benchmarks, with seven hotels receiving a Five-Star accolade in the 2026 Forbes Travel Guide. It is also the only integrated resort operator in Macao to add two new hotels to its portfolio: The Londoner^® Macao’s Paiza Grand, which received the coveted rating in its first year of operation, and The St. Regis Macao. These results put Sands China in the unrivalled leadership position of having the most Forbes Five-Star hotels under one roof, world-wide.

Sands China’s Forbes Five-Star award-winners for 2026 are:

Hotels

• Paiza Grand at Londoner Grand (Inaugural award)
• Londoner Court (4^th consecutive year)
• The Londoner Hotel (4^th consecutive year)
• Paiza Lofts at The Parisian^® Macao (3^rd consecutive year)
• The St. Regis Macao (Inaugural award)
• Four Seasons Hotel Macao (13^th consecutive year)
• The Grand Suites at Four Seasons (5^th consecutive year)

Restaurants

• The Huaiyang Garden at The Londoner Macao (2^nd consecutive year)
• Zi Yat Heen at Four Seasons Hotel Macao (4^th consecutive year)

Spa

• The Spa at Four Seasons Hotel Macao (7^th consecutive year) 

Grant Chum, President and Chief Executive Officer of Sands China Ltd. said, “We are thrilled to be recognised with a total of ten Forbes Five-Star accolades including seven Forbes Five-Star Hotels, an unprecedented achievement for a single integrated resort destination. Forbes Travel Guide is the world-renowned authority in the hospitality industry, and we are proud of our team for their accomplishments. Being honoured with these prestigious awards across our portfolio is an important milestone for Sands China and affirms our commitment to setting the highest industry standards. These unmatched results reflect both our dedication to excellence and our ambition to continually elevate Macao’s profile on the global tourism stage.”

Tane Picken, Chief Hospitality Officer – Asia, Las Vegas Sands Corp. added, “These awards attest to the passion, professionalism and dedication of our team members, who deliver exceptional services and experiences to every guest. We view each Five-Star rating as an honour and a responsibility, and we remain determined to consistently exceed guest expectations and deliver unsurpassed Sands Lifestyle experiences.”

Sands Dazzling Five-Star Portfolio
Atop Londoner Grand resides the 313-suite Paiza Grand, where a haven of British elegance awaits the most discerning guest, complemented by highly-trained Grand Butlers. Its crowning jewels are the six Hanover Suites. Bathed in natural light, these opulent two-bedroom suites have the ambience of a private oasis with large outdoor terrace and swimming pool. Forbes Travel Guide highlighted Paiza Grand’s appeal to VIP travellers and families, the personalised hospitality and the quality of rest that its spacious suites afford.

Other stellar offerings include Londoner Court, a 368-suite hotel where guests enjoy a residential London experience fit for royalty, enhanced by personal butler service; The Londoner Hotel, a 600-suite hotel, featuring a contemporary interpretation of classic British design; and Paiza Lofts, with 208 Parisian apartment-style suites, including the palatial, three-bedroom, Versailles Suite.

Completing Sands China’s Five-Star hotel recipients for 2026 are Four Seasons Hotel Macao, The Grand Suites at Four Seasons, and The St. Regis Macao, one of only two St. Regis properties in Greater China rated Forbes Five-Star.

Rounding out the Five-Star lineup this year are two-Michelin-starred The Huaiyang Garden at The Londoner Macao, Four Seasons’ Chinese restaurant Zi Yat Heen, and The Spa at Four Seasons Hotel Macao.

Forbes Travel Guide is the only independent, global rating system for luxury hotels, restaurants, and spas; evaluating based on up to 900 standards across facilities and service, with wellness and sustainability commitments also a factor in the final rating.

Paiza Grand at Londoner Grand – Lancaster Suite

Londoner Court – Mayfair Suite

The Londoner Hotel – Windsor Suite

Paiza Lofts at The Parisian Macao – Versailles Suite

Photo caption: Sands China Ltd. has many reasons to celebrate its 2026 Forbes Travel Guide results. This includes: a record-breaking seven hotels receiving a Five-Star accolade; the most Five-Star hotels under one roof, world-wide; and the only integrated resort operator in Macao to add two new Five-Star hotels to its portfolio.

Source: Sands China Ltd.

Source

SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ — Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) (“Ribo”) and its subsidiary Ribocure Pharmaceuticals AB (“Ribocure”) today announced that they have entered into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

The collaboration will utilize Ribo’s validated liver targeting siRNA GalSTAR^TM platform to develop novel treatments for MASH. The license agreement covers multiple existing pre-clinical assets from Ribo. In addition, both parties have the option to expand the scope of collaboration onto new siRNA programs including bi-specific siRNAs (agents that target two disease-causing genes simultaneously) utilizing Ribo’s unique GalSTAR^TM and siRNA chemical modification platforms.

We are enthusiastic to join forces with Madrigal Pharmaceuticals, drawing on their extensive knowledge together with our siRNA expertise to advance life changing therapies for people affected by liver disease, says Dr. Zicai Liang, CEO of Ribo.

To have the opportunity to work with the company that successfully launched the world’s first drug for MASH, a disease with rising prevalence and strong associations with numerous life-threatening comorbidities, is very encouraging. Leveraging our proprietary siRNA platform, we aim to expand the MASH therapeutic landscape through complementary, multi-mechanistic approaches, delivering more targeted and effective treatments for patients with unmet needs, says Dr Li-Ming Gan CEO of Ribocure and co-CEO of Ribo.

Financial Considerations
Under the agreement, Ribo has granted Madrigal an exclusive global license to develop, manufacture, and commercialize several siRNA assets. Ribo will receive an upfront payment of US$60M and cumulative payments could reach US$4.4B if certain development, regulatory and commercial milestones are achieved, as well as potential royalties on net sales.

About MASH

Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), is a serious liver disease that can progress to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. MASH is the leading cause of liver transplantation in women and the second leading cause of all liver transplantation in the U.S., and the fastest-growing indication for liver transplantation in Europe.

Once patients progress to MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), the risk of adverse liver outcomes increases dramatically: these patients have a 10-17 times higher risk of liver-related mortality as compared to patients without fibrosis. Those who progress to cirrhosis face a 42 times higher risk of liver-related mortality, underscoring the need to treat MASH before complications of cirrhosis develop. MASH is also an independent driver of cardiovascular disease, the leading cause of mortality for patients.

As MASH disease awareness improves and disease prevalence increases, the number of diagnosed patients with MASH with moderate to advanced fibrosis or compensated MASH cirrhosis (F2-F4c) is expected to grow.

About Suzhou Ribo Life Science Co. Ltd. and Ribocure Pharmaceuticals AB
Suzhou Ribo Life Science Co. Ltd. (HKEX: 6938) is an innovative clinical stage R&D company devoted to the development of nucleic acid drugs and related products based on the RNA interference (RNAi) technology. With its innovative R&D capabilities with vertically integrated technological platforms, Ribo has built a strong product pipeline, aiming to make contribution to the treatment of serious diseases with unmet medical needs.

As a subsidiary of Suzhou Ribo Life Science, Ribocure Pharmaceuticals AB is dedicated to globalized development of life-saving oligonucleotide therapies, with focus on development of assets and pipeline as well as new target ideas and on building innovative capacities to conduct clinical trials and developing siRNA drugs to address real unmet medical needs globally.

For more information, please visit www.ribolia.com and www.ribocure.com

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Source: Suzhou Ribo Life Science Co., Ltd.

Source

SINGAPORE, Feb. 11, 2026 /PRNewswire/ — In an era of noise, Light Stone Jewellery articulates a new dialect of quiet luxury through the silence of its forms. Unveiling a portfolio that functions as a “Wearable Culture Map,” the brand introduces a curatorial approach to designer jewellery, bridging the structural rigour of modern aesthetics with the profound resonance of Eastern antiquity.

Light Stone stands as an intellectual proposition for the contemporary woman. It rejects the transient nature of trend-driven fashion, choosing instead to anchor its identity in the permanence of the modern heirloom. The brand’s philosophy treats every necklace and earring as a geographical coordinate—a precise intersection where the weight of history meets the lightness of contemporary design. Simultaneously, the designs channel a “quiet power,” reflecting the inner strength of the contemporary woman—one who, like deep waters, remains composed and unaffected by the external noise of the world.

The Urban Planner’s Eye: Structure and Void

At the helm of this aesthetic system is Founder Jingjing, whose pedigree in Urban Planning and a Master in Management from ESCP Europe, combined with GIA certifications, informs the brand’s distinct architectural logic.

Jingjing approaches jewellery not merely as ornamentation, but as “Spatial Composition.”

“To me, a piece of jewelry is a coordinate,” says Founder Jingjing. “It maps the silence of history onto the modern body. I navigate the space between structure and instinct, applying the principles of urban planning—balance, void, and tension—to allow the wearer to inhabit the design, rather than simply display it.”

The Brutality of Perfection: The Celadon & Ru Kiln Collection

The core of the collection is the Celadon Tianqing (天青) Collection, a testament to the brand’s uncompromising standards. This series utilizes two primary elements: the nearly lost Ru Kiln technique and Longquan Celadon—a UNESCO Intangible Cultural Heritage.

Among these, the Ru Kiln pieces are exceptionally rare. The firing process requires temperatures exceeding 1380°C, with rare agate infused into the glaze to achieve the legendary “sky after rain” hue. The extreme chemical volatility of this process results in a high failure rate. Light Stone collaborates with master ceramicists to revive this millennial art, yet the selection criteria are ruthless. In every batch of Ru Kiln beads, those meeting the brand’s standard are far below 10%, often dropping to a mere 5%.

The majority are discarded for microscopic imperfections in form or glaze surface. Only the surviving 5-10%—possessing the perfect “Ice Crackle” texture and an unblemished jade-like warmth—are elevated into the Celadon Imperial Earrings. This scarcity is not manufactured; it is the physical residue of a structural dialogue between fire and gravity.

A Cartography of Four Dimensions

The “Wearable Culture Map” extends beyond porcelain, plotting four distinct aesthetic coordinates across China’s material history:

• The Silk Road (Dunhuang) Collection: Capturing the golden echoes of desert murals, these pieces translate ancient floral patterns into geometric gold vermeil structures.
• Totem (Majiayao) Collection: Drawing from prehistoric motifs, this series creates a primitive tension, turning Neolithic lines into bold, sculptural forms.
• Filigree (Huasi) Collection: A study in silver precision. This series deploys the imperial art of thread-weaving to build air-light structures that possess the strength of architectural steel.
• Celadon (Tianqing) Collection: The crystallization of silence, offering a tactile serenity that cools the skin and calms the mind.

The “Culture Map” is a living geography. Continuing its exploration of diverse regional craftsmanship, Light Stone has announced an upcoming expansion into the art of Lacquer, marking a new coordinate on this unfolding aesthetic journey.

About Light Stone Jewellery

Light Stone is a designer jewellery brand established in 2018 by founder Jingjing. The brand is dedicated to exploring the tension between “historical gravity and aesthetic ease.” Currently, Light Stone leverages dual studios and logistical hubs in Singapore and Shanghai, utilizing Singapore’s efficient global infrastructure to offer Global Priority Shipping. This ensures that every precious artistic asset reaches international collectors with speed and security.

Media Contact:
Email: marketing@lightstone-jewellery.com 
Website: www.lightstone-jewellery.com 

Source